Table 1.
VAV3 nuclear and cytoplasmic expression in relation to other tumor markers assessed by the Spearman’s rank correlation a
| |
Nuclear VAV3,
n
(%) |
Cytoplasmic VAV3,
n
(%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Score | – | 1+ | 2+ | 3+ | – | 1+ | 2+ | 3+ |
| All tumors |
607 (85.9) |
3 (0.4) |
43 (6.1) |
54 (7.6) |
229 (32.4) |
154 (21.8) |
215 (30.4) |
109 (15.4) |
| Tumor size (>20 mm vs. ≤20 mm) |
Rs = −0.04, P = 0.30 |
Rs = 0.13, P = 0.0009 |
||||||
| Tumor grade (1, 2 or 3) |
Rs = −0.09, P = 0.026 |
Rs = 0.16, P = 0.00007 |
||||||
| ERα (>10% vs. ≤10%) |
Rs = 0.05, P = 0.20 |
Rs = −0.12, P = 0.002 |
||||||
| PR (>10% vs. ≤10%) |
Rs = 0.06, P = 0.14 |
Rs = −0.15, P = 0.0002 |
||||||
| HER2 status (positive vs. negative) |
Rs = 0.00, P = 0.99 |
Rs = 0.05, P = 0.16 |
||||||
| Phospho-Ser167 ERα (%) |
Rs = 0.12, P = 0.002 |
Rs = −0.11, P = 0.003 |
||||||
| Phospho-Ser305 ERα (%) |
Rs = 0.11, P = 0.006 |
Rs = −0.09, P = 0.016 |
||||||
| PAK1 (cytoplasm 0 to 3 positivity) |
Rs = −0.07, P = 0.077 |
Rs = 0.12, P = 0.003 |
||||||
| Phospho-Ser473 AKT (nuclear %) |
Rs = 0.18, P < 0.00001 |
Rs = −0.20, P < 0.00001 |
||||||
| Phospho-Ser2448 mTOR (high vs. low) |
Rs = 0.06, P = 0.11 |
Rs = −0.08, P = 0.034 |
||||||
| Phospho-Ser65 4EBP1 (cytoplasm 0 to 2 positivity) |
Rs = −0.15, P = 0.0001 |
Rs = 0.19, P < 0.00001 |
||||||
| S6K2 (nuclear %) | Rs = 0.21, P < 0.00001 | Rs = −0.26, P < 0.00001 | ||||||
aERα, Estrogen receptor α; mTOR, mammalian target of rapamycin; PR, Progesterone receptor. P < 0.05 values are statistically significant.